Cardio Diagnostics 3Q 2026: Revenue $3.59K, EPS ($0.59) — 10-Q Summary
Cardio Diagnostics reported 3Q 2026 revenue of $3.59K, up 25.7% YoY, but net loss widened to $1.73M. The company added providers, began lab testing, and expanded coverage for its tests. EPS loss narrowed to $0.59 from $0.98.
How this was made

The 30-second read
Why it matters
The Q3 earnings indicate growth in revenue but continued operational losses, suggesting a mixed short‑term outlook.
Market read
Earnings release for a niche health‑tech micro‑cap; limited impact on broader markets.
What to watch
Potential future upside from new CLIA lab operations and expansion into India could improve margins.
Background
Cardio Diagnostics is a micro‑cap company providing cardiac diagnostic tests, recently expanding its provider network and lab capabilities.
Ticker impact
Cardio Diagnostics reported Q3 2026 revenue of $3.59M, a 25.7% YoY increase, and a narrowed net loss.
limited upside as revenue beats expectations, but pressure from widening loss may cap gains
Revenue beat suggests demand growth, yet expanding SG&A and net loss may dampen investor enthusiasm.
Market effects
Highlights ongoing demand for cardiac diagnostics, modestly positive for the broader health‑tech sector.
Primarily affects US micro‑cap investors; limited broader market effect.
Low global relevance beyond niche diagnostic market.
Counterpoint
Despite revenue growth, the widening loss and high SG&A suggest the stock may face further downside.
Key entities
- CompanyCardio Diagnostics Holdings, Inc.
Issuer of the earnings report.



